Results 141 to 150 of about 2,468 (182)

Management of Direct Oral Anticoagulants in Acute Type A Aortic Dissection. [PDF]

Aorta (Stamford)
Semco R, Faggion Vinholo T, Awtry J, Osho A, de la Cruz K, Sabe AA.   +5 more
europepmc   +1 more source

Managing bleeds on anticoagulant therapy: a practical guide for clinicians. [PDF]

Eur Heart J Acute Cardiovasc Care
Galli M, Simeone B, Ten Berg J, Capodanno D, Valgimigli M, Sciarretta S, Greco E, Kastrati A, Montalescot G, Gibson CM, Gorog DA, Mehran R, Angiolillo DJ.   +12 more
europepmc   +1 more source

Idarucizumab for dabigatran overdose

Clinical Toxicology, 2016
An overdose of oral anticoagulants represents a challenging scenario for emergency physicians. Dabigatran, an oral direct thrombin inhibitor, is increasingly used in place of warfarin. The lack of an antidote is a concern in patients who overdose on dabigatran, even though the drug can be eliminated with hemodialysis.
Laurens Liesenborghs, Peter Verhamme, Jeffrey Weitz   +2 more
exaly   +4 more sources

Idarucizumab for Dabigatran Reversal

New England Journal of Medicine, 2015
Specific reversal agents for non-vitamin K antagonist oral anticoagulants are lacking. Idarucizumab, an antibody fragment, was developed to reverse the anticoagulant effects of dabigatran.We undertook this prospective cohort study to determine the safety of 5 g of intravenous idarucizumab and its capacity to reverse the anticoagulant effects of ...
Pollack Jr, C.V., Reilly, P.A., Eikelboom, J., Glund, S., Verhamme, P., Bernstein, R.A., Dubiel, R., Huisman, M.V., Hylek, E.M., Kamphuisen, P.W., Kreuzer, J., Levy, J.H., Sellke, F.W., Stangier, J., Steiner, T., Wang, B., Kam, C.W., Weitz, J.I.   +17 more
openaire   +4 more sources

Some of the next articles are maybe not open access.

Related searches:

Idarucizumab

Circulation, 2015
Four non–vitamin K antagonist oral anticoagulants (NOACs), including the direct thrombin inhibitor dabigatran and the direct factor Xa inhibitors rivaroxaban, apixaban, and edoxaban, are currently licensed as alternatives to heparins and vitamin K antagonists for the prevention and treatment of venous thromboembolism and for the prevention of stroke in
Jeffrey Weitz, John Eikelboom, Joanne van Ryn   +2 more
exaly   +3 more sources

Assessment of patients post reversal with idarucizumab

Journal of Thrombosis and Thrombolysis, 2018
Idarucizumab, a fully humanized Fab antibody fragment, is indicated for reversal of dabigatran's anticoagulant activity. Idarucizumab neutralizes the anticoagulant effects of dabigatran by binding to dabigatran and its metabolite. In the full analysis of 503 patients, idarucizumab fully reversed the anticoagulant effect of dabigatran in more than 98 ...
Veronica Raco, Tania Ahuja
exaly   +3 more sources

Real-world experience with reversal of dabigatran by idarucizumab [PDF]

Thrombosis Research, 2021
Aims: Idarucizumab reverses the anticoagulant effect of dabigatran. We aimed to investigate real-world experience with idarucizumab and associated clinical outcomes.
Erik Grove, Mads Nybo, Anne-Mette Hvas   +2 more
exaly   +2 more sources

Idarucizumab: What Should We Know?

Current Drug Targets, 2018
BACKGROUND: Idarucizumab, a humanized monoclonal antibody fragment acting as specific antidote for dabigatran, is approved for reversing the dabigatran-associated possible bleeding from critical sites or bleeding persisting despite local post-procedure ...
Annagrazia Cecere, Francesca Cortese, Michele Gesualdo   +2 more
exaly   +2 more sources

Idarucizumab

Hospital Pharmacy, 2016
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing ...
Dennis J, Cada, Anne P, Kim, Danial E, Baker   +2 more
openaire   +3 more sources

Performance of idarucizumab as antidote of dabigatran in daily clinical practice [PDF]

Europace, 2019
AIMS: Because practice-based data on the usage of idarucizumab for urgent dabigatran reversal is unavailable, we evaluated the appropriateness of idarucizumab usage, its haemostatic effectiveness and clinical outcomes.
Sake van der Wall, Nienke van Rein, Karina Meijer   +2 more
exaly   +3 more sources